THORN AND ZUMTOBEL LIGHTING ANNOUNCE CANCER RESEARCH UK AS CHARITY PARTNER FOR 2024/25
UK, September 2024 – Thorn and Zumtobel UK and Ireland, lighting brands of the Zumtobel Group, are delighted to announce their partnership with Cancer Research UK as the chosen charity for the 2024/25 financial year. Following an internal survey, employees overwhelmingly voted for Cancer Research UK, recognising the organisation's crucial role in the fight against cancer.
Cancer survival rates have improved significantly over the years. In the 1970s, only 1 in 4 people with cancer survived their disease for ten years or more. Today, this figure has doubled to 2 in 4 people. Cancer Research UK aims to accelerate progress so that in the next 20 years, 3 in 4 people will survive cancer for at least a decade.
Paul Kilburn, Managing Director Thorn and Zumtobel Lighting UK and Ireland, expressed his enthusiasm for the partnership: "We are proud to support Cancer Research UK and their mission to improve cancer survival rates. Our team is committed to making a difference, and we are confident that, together, we can contribute significantly to the fight against cancer."
Jan Leafe, Relationship Manager at Cancer Research UK, shared her gratitude: "It means a lot to us that the Thorn and Zumtobel has chosen to partner with Cancer Research UK, and we're here to support to the finish line with training and fundraising tips. At Cancer Research UK, our vision is to bring about a world where everyone can live longer, better lives and be free from the fear of cancer. We've made huge progress already, but we have much further to go – and we can't do it without organisational support. Every step we take relies on every pound donated. So, whether you're raising £250 or £2,500, you're supporting our vital work that will make a difference to people affected by cancer, now and in the future."
Thorn and Zumtobel look forward to a successful year of fundraising and awareness-raising activities in collaboration with Cancer Research UK, contributing to their vital work in cancer research and treatment advancements.
